A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis

Emmanouil Charakopoulos, MD, Ioannis Spyrou, MD, Nora-Athina Viniou, MD, PhD, Nefeli Giannakopoulou, MD, Sebastianos Hatzidavid, MD, Panagiotis Theodorou Diamantopoulos, MD, PhD

Abstract

Rationale: Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymphoma in a psoriatic patient receiving ustekinumab.

Patient concerns: A 22-year-old asymptomatic female patient presented to our department to investigate an enlarged cervical lymph node. Her past history was unremarkable, except for psoriasis since age 13. Two months before presentation the decision to administer Ustekinumab was taken and the patient had already received 3 doses.

Diagnoses: During workup a Stage IV Hodgkin lymphoma was discovered.

Interventions: Ustekinumab administration was discontinued. The patient received treatment with the ABVD regimen.

Outcomes: The patient’s disease was refractory to the above-mentioned treatment. Therefore, a more aggressive regimen (BEACOPP escalated) was administered.

Lessons: Growing postmarketing surveillance data and case reports indicate that further research is warranted in order to elucidate a potential association between Ustekinumab and malignancy.

Abbreviations: FDA = Food and Drug Administration, HL = Hodgkin lymphoma, IL = interleukin.

Keywords: Hodgkin lymphoma, psoriasis, ustekinumab

1. Introduction

Ustekinumab (Stelara) is a new biologic agent, which is primarily used in the treatment of moderate to severe plaque psoriasis. It has been proven to be effective and safe in the vast majority of studies, but there are case reports of malignancies that have been associated with ustekinumab administration. We present a case of a young female patient who was diagnosed with Hodgkin lymphoma (HL) 2 months after treatment initiation with ustekinumab for severe psoriasis. In the literature, we detected similar reports that correlated ustekinumab with hematologic malignancies, more specifically multiple myeloma, cutaneous T-cell lymphoma, and gastric mucosa-associated lymphoid tissue lymphoma.

2. Case presentation

A 22-year-old woman with chronic plaque psoriasis since the age of 13, and an otherwise unremarkable past medical history, was diagnosed with HL after being evaluated for a painless enlarged supraclavicular lymph node. There was no account of B-symptoms. The family history had also been negative for malignancy. The patient is a former smoker (3.5 pack-years exposure) and drinks socially. No allergies were reported.

In the initial workup that followed the clinical examination, white blood cell and platelet counts were slightly elevated, with $11 \times 10^9$cells/L and $480 \times 10^9$platelets/L respectively; the remaining values of the complete blood count and routine biochemical assays were within normal range. An excisional biopsy was performed and the pathology examination established the diagnosis of HL, subtype nodular sclerosis. For staging purposes, a bone marrow biopsy and imaging studies were performed. A positron emission tomography/computed tomography demonstrated multiple foci of increased bone marrow uptake, suspicious of malignant infiltration. The bone marrow biopsy reported focal reactive changes with dysplastic features, with no confirmed infiltration by HL. Imaging revealed an extensive lymph node involvement (cervical, axillary, mediastinal, pulmonary hilar bilaterally, splenic hilar, left inguinal, paraaortic, iliac, and mesenteric nodes). Finally, a solitary slightly hypermetabolic nodular lesion was detected in the left lung parenchyma, which was; however, deemed unlikely to stem from...
lymphoma cells. Thus, the disease was determined to be stage IV with the Cotswold modification of the Ann Arbor staging system.

The patient was treated with ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) according to the common clinical practice in our institution, in an outpatient setting; an interim positron emission tomography/computed tomography was performed after the second cycle. Abnormally hypermetabolic lymph nodes were detected in the cervical, thoracic and abdominal region; these included paratracheal and anterior mediastinal lymph nodes, as well as 2 foci in the splenic parenchyma among other sites (4 points in the Deauville scoring scale indicating active residual disease).

The drug regimen was modified to BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone).

Regarding the course of psoriasis, it is worth mentioning that the initial psoriatic plaque was located on the scalp; therefore, a topical corticosteroid was prescribed. However, patient adherence to treatment was poor and psoriatic lesions were generalized along the extremities and trunk over a 2-year period. The treating dermatologist opted for a combination of topical treatments which led to partial regression of the psoriatic plaques, over the next 6 years. Ultimately, 2 months before the diagnosis of HL, treatment with ustekinumab was started. A dose of 90mg (according to the patient’s weight) was administrated subcutaneously at that point; another dose followed 1 month later and the last one a few days before the diagnosis of HL. The treatment led to complete regression of the cutaneous lesions, even from the first injection of ustekinumab. Because of the diagnosis of HL, ustekinumab was discontinued. Lesions then gradually recurred on the scalp of the patient in the next months and are now under partial control with the application of budesonide, mometasone, salicylic acid, and an emollient cream.

3. Discussion

Ustekinumab is a new monoclonal antibody that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe psoriasis since 2009.[19] Its mechanism of action is unique: it binds to and inhibits the common subunit (p40) of Interleukin (IL) 12 and 23; therefore, reducing in inflammation through the activation of T-helper 1 and T-helper 17 cells respectively.[20,21] Other indications of ustekinumab are Crohn disease, psoriatic arthritis, and relapsing multiple sclerosis.[19]

Despite the fact that the simultaneous blockade of the IL-12 and IL-23 pathway is oncogenic in experimental animal models,[22,23] the safety and efficacy of ustekinumab in the treatment of psoriasis has been well demonstrated in 3 phase III clinical trials: PHOENIX 1,[19] PHOENIX 2,[24] and ACCEPT.[25] The most common side effect was grade 2 upper airway tract infections (according to Common Terminology Criteria for Adverse Events v4.0).[26] Although there were reports of malignancies, there was no observable statistically significant difference compared to the placebo groups.[19] However, the results of those trials cannot guarantee the long term safety of ustekinumab. An instructive example is efalizumab, which had been proven to be effective and safe in the treatment of psoriasis by inhibiting the leukocyte function-associated antigen 1 before its withdrawal from the market in 2009, because of its potential to cause progressive multifocal leukoencephalopathy.[28]

Several authors in the literature report cases of malignancies in patients treated with ustekinumab.[12–16] These cases are displayed concisely in Table 1.

Nevertheless, before attributing the patient’s HL to ustekinumab, the inherent risk of malignancy in psoriatic patients should also be taken into consideration. Several studies have shown an overall increased cancer risk in patients with psoriasis, even before the use of biologics in its treatment. Lymphoma, nonmelanoma skin cancer, and cancers associated with smoking and alcohol consumption are the most consistently reported malignancies.[30–42] The risk of developing cancer is proportionate to disease severity,[30,32] and might be influenced by gender and age. Young males seem to represent the group at the highest risk.[42]

The increased risk of lymphoma in psoriasis is consistent with the pathophysiology of this chronic inflammatory skin disease, because it is characterized by a diffuse cytokine-induced immunological activation.[32] Psoriasis has been shown to increase the risk of all lymphoma types,[30,31,36,39,43,44] especially of HL according to some studies.[30,39] Gu et al conclude that psoriasis might also increase the risk of lymphoma in pediatric patients.[43] Because of the above evidence, we cannot exclude the possibility that our patient’s HL is spontaneous or that it is associated with psoriasis and not ustekinumab, but the emergence of such an advanced lymphoma after the initiation of treatment makes these alternative hypotheses less probable.

On the other hand, the relatively short treatment duration cannot fully explain the development of such an advanced tumor. Experiments in primates showed that the administration of an extremely high dose of IL-12/IL-23 inhibitor did not cause cancer

| Authors | Indication for ustekinumab | Duration of ustekinumab administration – cumulative dose at tumor appearance | Ensuing malignancy and stage |
|---------|---------------------------|-------------------------------------------------|-------------------------------|
| Young et al[32] | Psoriasis | 4 mo – 135 mg | Squamous cell carcinoma (Stage I-II) |
| Young et al[32] | Psoriasis | 1 mo – 90 mg | Squamous cell carcinoma (Stage I-II) |
| Ehrmann et al[44] | Crohn disease | 12 mo – 225 mg | Malignant melanoma (Stage I) |
| Humme et al[33] | Phyllodes tumor of the breast | 12 mo | Cutaneous T-cell lymphoma (Stage III) |
| Gonzalez-Fuentes et al[15] | Psoriasis | 18 mo | Gastric MALT lymphoma (Stage I) |
| Pinto-Almeida[44] | Psoriasis | 18 mo – 315 mg | Multiple myeloma (Stage IVA according to the Durie-Salmon staging system) |

MALT = mucosa-associated lymphoid tissue.
for a minimum of 6 months. Therefore, it could be hypothesized that ustekinumab led to an exacerbation of an already existing subclinical malignancy in our patient. This assumption is in agreement with the supposition of Young and Czarnecki, who claim that the immunosuppressive effect of ustekinumab might cause a subclinical malignancy to become apparent. As mentioned in the relative prescription information of Stelara, little is known about the effects of ustekinumab in patients with a known cancer, because most patients with a history of malignancy were excluded from PHOENIX 1, PHOENIX 2, and ACCEPT trials as ineligible.

More studies are needed to determine if a known history of malignancy represents a contraindication to the initiation of treatment with ustekinumab. In November 2017, Florek et al, as part of the postmarket surveillance between 2001 and 2016, reported a detected safety signal in the voluntary FDA Adverse Event Reporting System concerning B-cell lymphoma, lung, thyroid, and ovarian cancer among others; similar reports arose also in the EudraVigilance database. Despite the possible presence of reporting bias, and the lack of details that could augment our effort to establish potential causality (dose, duration of exposure, timing of manifestation of malignancy) and elucidate possible confounding factors and after taking into account the fact that a causal relationship need not be determined for the FDA in these reports, it should be emphasized that postmarket surveillance garners real world data that may elude randomized control trials. Therefore, it is clear that further long term studies are warranted to investigate the possible link between ustekinumab and the risk of malignancy.

4. Conclusions

In conclusion, ustekinumab might increase the risk of certain malignancies. This is in accordance with various case reports and postmarket surveillance data. To our knowledge, this is the first recorded case of a HL in a patient receiving ustekinumab. More studies are needed to determine a potential link between ustekinumab and cancer.

Author contributions

Conceptualization: Nora-Athina Viniou, Nefeli Giannakopoulou, Sebastiános Hatzidavid, Panagiotis T. Diamantopoulos.

Formal analysis: Emmanouil Charakopoulos.

Methodology: Emmanouil Charakopoulos, Ioannis Spyrou, Panagiotis T. Diamantopoulos.

Project administration: Ioannis Spyrou, Nefeli Giannakopoulou, Sebastiános Hatzidavid.

Resources: Emmanouil Charakopoulos.

Software: Emmanouil Charakopoulos.

Supervision: Nora-Athina Viniou, Panagiotis T. Diamantopoulos.

Validation: Panagiotis T. Diamantopoulos.

Writing – original draft: Emmanouil Charakopoulos, Ioannis Spyrou.

Writing – review and editing: Emmanouil Charakopoulos, Ioannis Spyrou.

References

[1] Feldman SR. Treatment of Psoriasis in Adults. UpToDate. 2017. Available at: https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults. [Accessed on February 10, 2018]

[2] Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol 2014;39:696–707.

[3] Kruigel E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010;5:11–22.

[4] Santos-Juanes J, Coto P, Galache C. Ustekinumab. Neoplasias y otros aspectos de seguridad. Actas Dermosifiliogr 2012;103:39–44.

[5] Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology 2015;230:46–54.

[6] Magnano M, Loi C, Sechi A, et al. Risk of malignancy in psoriatic patients: our clinical experience. Dermatol Ther 2017;30:61–47.

[7] Napolitano M, Megna M, Patri A, et al. Systemic treatment for psoriasis and malignancies: a real risk? Dermatol Ther 2017;30:12508.

[8] Leonard CI, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1663–74.

[9] Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844–54.

[10] Young L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012;53:57–60.

[11] Humme D, Beyer M, Rowett-Huber H-J, et al. CD30-positives anaplastisch großzelliges T-zell-lymphom unter immunosuppressiver therapie einer pcitis rubra pilaris mut ustekinumab. Hautarzt 2013;64:190–4.

[12] Elhmann LM, Tillack-Schreiber C, Brand S, et al. Malignant melanoma during ustekinumab therapy of Crohn’s disease. Inflamm Bowel Dis 2012;18:E199–200.

[13] Gonzalez-Ramos J, Alonso-Pacheco ML, Mayor-Ibarguren A, et al. Gastric mucosa-associated lymphoid tissue lymphoma in a patient with severe psoriasis receiving ustekinumab. Actas Dermosifiliogr 2015;106:326–7.

[14] Pinto-Almeida T, Torres T, Selores M. Multiple myeloma in a patient under ustekinumab—are they related? Eur J Acad Dermatol Venereol 2017;31:e40–1.

[15] Tesmer LA, Lundy SK, Sarkar S, et al. Deauville Five-point Scale. Radiopaedia. Available at: https://radiopaedia.org/articles/deauville-five-point-scale. [Accessed on December 30, 2018]

[16] Wofford J, Menter A. Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2014;10:189–202.

[17] Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag 2010;6:123–41.

[18] Tamura CE, Gordon K, et al. Long-term safety of ustekinumab in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:977–87.

[19] Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1663–74.

[20] Bell DJ, Pfleger R. Deauville Five-point Scale. Radiopaedia. Available at: https://radiopaedia.org/articles/deauville-five-point-scale. [Accessed on December 30, 2018]

[21] Lemley MV, Emery P, Khamasah N, et al. Comparison of tumour necrosis factor antagonists for patients with rheumatoid arthritis. Expert Rev Clin Immunol 2014;10:189–202.

[22] Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag 2010;6:123–41.

[23] Tesmer LA, Lundy SK, Sarkar S, et al. Th17 cells in human disease. Immunol Rev 2008;223:81–93.

[24] Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933–44.
[27] Boehncke WH. Efalizumab in the treatment of psoriasis. Biologics 2007;1:301–9.
[28] Seminara NM, Gelfand JM. Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 2010;29:16–9.
[29] Kimball AB, Schenfeld J, Accortt NA, et al. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol 2015;173:1183–90.
[30] Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194–201.
[31] Frenz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237–42.
[32] Lee MS, Lin RY, Chang YT, et al. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol 2012;51:1454–60.
[33] Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol 2017;76:639–47.e2.
[34] Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425–9.
[35] Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531–7.
[36] Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 2009;129:2604–12.
[37] Kimball AB, Schenfeld J, Accortt NA, et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol 2014;170:366–73.
[38] Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol 2016;152:282–90.
[39] Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587–90.
[40] Dai H, Li WQ, Qureshi AA, et al. Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: a population-based cohort study. J Am Acad Dermatol 2016;75:731–5.
[41] Egeberg A, Thyssen JP, Gislason GH, et al. Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol 2016;30:1349–53.
[42] Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011;65:84–91.
[43] Margolis D, Billker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778–83.
[44] Ji J, Shu X, Sundquist K, et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009;100:1499–502.
[45] Gu Y, Nordstrom BL. The risk of malignancy among biologic-naive pediatric psoriasis patients: a retrospective cohort study in a US claims database. J Am Acad Dermatol 2017;77:293–301.e1.
[46] Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001–17.
[47] Janssen Pharmaceutical Companies. Stelara (ustekinumab) [package insert]. U.S. Food and Drug Administration website. Revised October 2017. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125261s138lbl.pdf. [Accessed on February 10, 2018]
[48] Florek AG, Nardone B, Tharja S, et al. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database. Br J Dermatol 2017;177:e220–1.